MoonLake Immunotherapeutics

Equities

MLTX

KY61559X1045

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
40.92 ^USD	-2.50%		-9.59%	-32.24%

May. 07	MoonLake Immunotherapeutics Q1 Net Loss Widens	MT
May. 07	MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

MoonLake Immunotherapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 29, 2024 at 08:04 am EST

MoonLake Immunotherapeutics reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 0.450315 million. Basic loss per share from continuing operations was USD 0.12.

Latest news about MoonLake Immunotherapeutics

MoonLake Immunotherapeutics Q1 Net Loss Widens	May. 07	MT
MoonLake Immunotherapeutics Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 07	CI
MoonLake Immunotherapeutics, Komodo Health Team Up to Improve Inflammatory Skin, Joint Diseases Treatment	Apr. 10	MT
Goldman Sachs Initiates MoonLake Immunotherapeutics at Neutral With $62 Price Target	Apr. 02	MT
Health Care Dips Amid Regulatory Doubts -- Health Care Roundup	Mar. 11	DJ
HC Wainwright Adjusts Price Target on MoonLake Immunotherapeutics to $100 From $75, Maintains Buy Rating	Mar. 11	MT
MoonLake Immunotherapeutics Announces Significant Improvements with Nanobody Sonelokimab over 24 Weeks in Active Psoriatic Arthritis	Mar. 10	CI
Moonlake Immunotherapeutics to Present MIRA Trial Data of Nanobody Sonelokimab in Hidradenitis Suppurativa as A Late Breaker At the AAD Annual Meeting 2024	Mar. 04	CI
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,803,044, According to a Recent SEC Filing	Mar. 01	MT
Moonlake Immunotherapeutics Insider Sold Shares Worth $6,540,710, According to a Recent SEC Filing	Mar. 01	MT
MoonLake Immunotherapeutics Shares Decline After Posting Q4 Loss	Feb. 29	MT
MoonLake Immunotherapeutics Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
MoonLake Immunotherapeutics Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
MoonLake Gains FDA, EMA Backing For Late-Stage Hidradenitis Suppurativa Trial	Feb. 26	MT
Moonlake Immunotherapeutics Insider Sold Shares Worth $1,208,418, According to a Recent SEC Filing	Feb. 23	MT
Wolfe Research Initiates MoonLake Immunotherapeutics With Outperform Rating, $77 Price Target	Feb. 15	MT
Moonlake Immunotherapeutics Insider Sold Shares Worth $5,917,368, According to a Recent SEC Filing	Dec. 21	MT
Stifel Adjusts Price Target on MoonLake Immunotherapeutics to $69 From $66, Maintains Buy Rating	Dec. 18	MT
Citigroup Starts MoonLake Immunotherapeutics With Buy Rating, $72 Price Target	Dec. 08	MT
Wedbush Raises MoonLake Immunotherapeutics' Price Target to $92 From $86, Maintains Outperform Rating	Nov. 16	MT
Guggenheim Adjusts MoonLake Immunotherapeutics' Price Target to $77 From $70, Maintains Buy Rating	Nov. 14	MT
MoonLake Immunotherapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 14	CI
MoonLake Immunotherapeutics Says Phase 2 Trial of Nanobody Sonelokimab Met Primary Endpoint	Nov. 06	MT
MoonLake Immunotherapeutics Announces Landmark Phase 2 Results for Nanobody Sonelokimab in Active Psoriatic Arthritis	Nov. 05	CI
MoonLake Immunotherapeutics Stock Up 13% on Positive Data for Skin Condition Treatment	23-10-16	DJ

Chart MoonLake Immunotherapeutics

Duration

Period

More charts

Company Profile

MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.

Sector

Biotechnology & Medical Research

Calendar

2024-06-04 - Jefferies Healthcare Conference

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

40.92 USD

Average target price

73.38 USD

Spread / Average Target

+79.34%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
MOONLAKE IMMUNOTHERAPEUTICS	-32.24%	2.57B
VERTEX PHARMACEUTICALS INCORPORATED	+3.91%	109B
REGENERON PHARMACEUTICALS, INC.	+10.87%	105B
ARGENX SE	+1.28%	22.25B
BIONTECH SE	-13.14%	22.09B
GENMAB A/S	-7.05%	18.68B
WUXI APPTEC CO., LTD.	-38.36%	17.58B
BEIGENE, LTD.	-10.66%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.75%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.70%	12.46B

Bio Therapeutic Drugs